December 10, 2018: Santhera’s Board of Directors Submits Amended Proposal to its Extraordinary General Meeting on December 11, 2018
November 20, 2018: Santhera Calls Extraordinary General Meeting and Proposes Ordinary Share Capital Increase to Raise Approximately CHF 50 Million
November 20, 2018: Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone
October 24, 2018: Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis
October 15, 2018: Santhera Receives Positive Opinion for Orphan Drug Designation in the EU for POL6014 in Cystic Fibrosis
September 04, 2018: Santhera Announces Financial Results for the First Half-Year 2018 and Updates on Operational Progress and Growth Strategy Conference Call 13:00 CEST (audio file mp3)
August 21, 2018: Santhera to Report First Half-Year Financial Figures and Provide Corporate Update on September 4, 2018
July 05, 2018: Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy
June 22, 2018: UK’s MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera’s Raxone® (idebenone) in Duchenne Muscular Dystrophy
April 12, 2018: Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
April 05, 2018: Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy
March 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy
March 05, 2018: Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
February 15, 2018: Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases
February 06, 2018: Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)
January 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update
January 26, 2018: Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in Duchenne Muscular Dystrophy
January 24, 2018: Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy
January 19, 2018: Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures
